DARA is a fully humanized IgG1 κ mAb targeting CD38, which kills MM cells through immune mechanisms of action, including complement-dependent cellular cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP) [25,26] (Table 1). The gene discussed is CD38; the disease is Miyoshi myopathy.